Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diampromide is a synthetic opioid analgesic of the ampromide family, structurally related to propiram and phenampromide, and can be described as a ring-opened analogue of fentanyl. It was invented in the 1960s by American Cyanamid. Pharmacologically, it acts as an opioid agonist with effects similar to morphine, including analgesia, sedation, dizziness, and nausea. Its potency is approximately equivalent to morphine in animal models. It has been evaluated for postoperative pain but is not approved or marketed for medical use in any country. Diampromide is classified as a Schedule I controlled substance under the United States Controlled Substances Act and under international conventions due to its high potential for abuse and lack of accepted medical use[1][4][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diampromide.